PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Both yoy net incomes decline, with TRVN at -113.85%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
8.11%
Some D&A expansion while TRVN is negative at -1.80%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
14.88%
Some yoy growth while TRVN is negative at -200.00%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
33.33%
SBC growth well above TRVN's 6.73%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-359.86%
Negative yoy working capital usage while TRVN is 103.18%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Both reduce yoy usage, with TRVN at -94.85%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-14.88%
Negative yoy while TRVN is 4.44%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-25.31%
Both yoy CFO lines are negative, with TRVN at -161.92%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-2962.50%
Negative yoy CapEx while TRVN is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
We reduce yoy invests while TRVN stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
56.30%
Debt repayment above 1.5x TRVN's 33.33%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
23135.79%
We slightly raise equity while TRVN is negative at -92.12%. John Neff sees competitor possibly preserving share count or buying back shares.
100.00%
Buyback growth of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.